Kriti Industries Files Monitoring Agency Report for Q4 FY26 Preferential Issue Fund Utilisation
Kriti Industries (India) Limited filed the Monitoring Agency report by CARE Ratings for Q4 FY26 under Regulation 32(6), alongside a NIL Statement of Deviation under Regulation 32(1). The lapse of 63,69,000 preferential warrants resulted in a Rs. 75.71 crore shortfall, prompting the Board to revise the overall fund objective from Rs. 149.96 crore to Rs. 74.25 crore. All revised fund objectives — working capital (Rs. 40.00 crore) and capex (Rs. 34.25 crore) — have been fully utilised with no unutilised proceeds as of 31st March, 2026.

*this image is generated using AI for illustrative purposes only.
Kriti Industries (India) Limited has submitted the Monitoring Agency report of CARE Ratings Limited pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended 31st March, 2026. The submission, dated 11th May, 2026, accompanies the company's earlier NIL Statement of Deviation filed under Regulation 32(1), and provides a comprehensive update on the utilisation of proceeds from the preferential issue. Notably, the report highlights a significant shortfall in fund receipts following the lapse of 63,69,000 warrants, which led to a revision of the overall fund objective.
Fund Raising and Warrant Lapse
The preferential issue was originally intended to raise Rs. 149.96 crore. However, warrant holders of 63,69,000 warrants did not exercise the option to convert the said warrants into equity shares within the stipulated period of 18 months from the date of allotment, i.e., on or before 26th January, 2026. Accordingly, the said warrants have lapsed and stand cancelled, and no equity shares have been allotted against them. This resulted in a shortfall of Rs. 75.71 crore in fund receipts. Consequently, the company received only Rs. 74.25 crore against the originally planned Rs. 149.96 crore, and the Board, in its meeting dated February 05, 2026, approved a revision of the overall fund objective to Rs. 74.25 crore.
The following table summarises the key issue and fund utilisation details as reported for the quarter ended 31st March, 2026:
| Parameter: | Details |
|---|---|
| Type of Issue: | Preferential Share Warrants Issue |
| Issue Period: | 18 months from date of allotment i.e. July 27, 2024 |
| Original Issue Size: | Rs. 149.96 crore |
| Amount Received: | Rs. 74.25 crore |
| Shortfall in Funds: | Rs. 75.71 crore |
| Warrants Lapsed/Cancelled: | 63,69,000 warrants |
| Monitoring Agency: | CARE Ratings Limited |
| Deviation/Variation: | No |
Revised Object-Wise Fund Utilisation
Following the shortfall in fund receipts, the company revised the cost allocation across its stated objects. The working capital objective remained unchanged at Rs. 40.00 crore, while the capital expenditure for expansion was revised downward from Rs. 80.00 crore to Rs. 34.25 crore. The general corporate purpose allocation, originally set at Rs. 30.00 crore, was reduced to nil. The table below presents the original and revised cost allocations along with utilisation progress as of the quarter ended 31st March, 2026:
| Object: | Original Cost (Rs. Crore) | Revised Cost (Rs. Crore) | Amount Utilised at End of Quarter (Rs. Crore) | Unutilised Amount (Rs. Crore) |
|---|---|---|---|---|
| Working Capital for existing business and proposed new facilities: | 40.00 | 40.00 | 40.00 | - |
| Capital Expenditure for expansion of capacity by adding new manufacturing lines for Pipes: | 80.00 | 34.25 | 34.25 | - |
| General Corporate Purpose: | 30.00 | - | - | - |
| Total: | 150.00 | 74.25 | 74.25 | - |
The working capital objective was fully completed in Q4 FY25. During the quarter ended 31st March, 2026, Rs. 0.52 crore was utilised towards capital expenditure — specifically for stamp duty, registration fees for purchase of land, and purchase of machinery — bringing the total capex utilisation to Rs. 34.25 crore, which equals the revised cost for that object. There are no unutilised proceeds as of 31st March, 2026.
Monitoring Agency Observations
CARE Ratings Limited, acting as the Monitoring Agency under the Monitoring Agency Agreement dated July 24, 2024, confirmed that all utilisation is as per the disclosures in the Board Meeting Resolution. The agency noted that the means of finance for the disclosed objects have changed due to the shortfall in fund receipts, and that the envisaged benefits from the capex plan may not fully materialise as a result. The company had onboarded a consultancy firm for setting up a new manufacturing line, and technical assistance arrangements remain in operation. No material deviation was observed over earlier monitoring agency reports. The Chartered Accountant certificate relied upon for this report was issued by M/s. M. Mehta & Co., dated May 01, 2026.
Compliance and Signatories
The Monitoring Agency report was prepared and signed by Anuja Parikh, Associate Director, CARE Ratings Limited, and submitted to the Board of Directors of Kriti Industries (India) Limited on 11th May, 2026. The company's submission to the stock exchanges was signed by Aditi Randhar, Company Secretary and Compliance Officer. The company had earlier also filed the NIL Statement of Deviation under Regulation 32(1) for the same quarter, which was signed jointly by Aditi Randhar and Rajesh Sisodia, Chief Financial Officer, on 5th May, 2026, confirming no deviation or variation in fund utilisation against the stated objects.
Historical Stock Returns for Kriti Industries India
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.46% | -1.61% | +4.28% | -22.33% | -28.31% | -29.71% |
How will the Rs. 45.75 crore reduction in capital expenditure impact Kriti Industries' planned capacity expansion timeline and its ability to compete in the pipes manufacturing market?
What are the likely reasons behind warrant holders forfeiting 63,69,000 warrants worth Rs. 75.71 crore, and could this signal broader investor confidence concerns about the company's growth prospects?
With general corporate purpose funding completely eliminated from the revised plan, how will Kriti Industries finance its operational flexibility and any unforeseen business needs going forward?
































